How often does treatment of primary HIV lead to post-treatment control?

Antiviral Therapy

Volumn 20, Issue 8, 2015, Pages 855-863

  Maenza, Janine ^a   Tapia, Kenneth ^a   Holte, Sarah ^a,b   Stekler, Joanne D ^a   Stevens, Claire E ^a   Mullins, James I ^a   Collier, Ann C ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ANTIRETROVIRUS AGENT; ATAZANAVIR; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; EFAVIRENZ; EMTRICITABINE; INDINAVIR; INTEGRASE INHIBITOR; LOPINAVIR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; VIRUS RNA; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFECTION CONTROL; MALE; NONHUMAN; OBSERVATIONAL STUDY; POSTTREATMENT CONTROL; PRIORITY JOURNAL; VIRUS LOAD; CD4 LYMPHOCYTE COUNT; HIV INFECTIONS; KAPLAN MEIER METHOD; TIME FACTOR; TREATMENT FAILURE; TREATMENT OUTCOME; VIREMIA; VIROLOGY;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; RNA, VIRAL; TIME FACTORS; TREATMENT FAILURE; TREATMENT OUTCOME; VIREMIA;

EID: 84973574815     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2963     Document Type: Article

References (18)

1. Sáez-Cirión A, Bacchus C, Hocqueloux L, et al. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI study. PLoS Pathog 2013; 9:e1003211.
2. Kaslow RA, Carrington M, Apple R, et al. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat Med 1996; 2:405-411.
3. Migueles SA, Sabbaghian MS, Shupert WL, et al. HLA B∗5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc Natl Acad Sci U S A 2000; 97:2709-2714.
4. Schacker T, Collier AC, Hughes J, Shea T, Corey L. Clinical and epidemiologic features of primary HIV infection. Ann Intern Med 1996; 125:257-264.
5. Schacker TW, Hughes JP, Shea T, Coombs RW, Corey L. Biological and virologic characteristics of primary HIV infection. Ann Intern Med 1998; 128:613-620.
6. Stekler JD, Wellman R, Holte S, et al. Are there benefits to starting antiretroviral therapy during primary HIV infection? Conclusions from the Seattle Primary Infection Cohort vary by control group. Int J STD AIDS 2012; 23:201-206.
7. Carrington M, O'Brien SJ. The influence of HLA genotype on AIDS. Annu Rev Med 2003; 54:535-551.
8. Itescu S, Mathur-Wagh U, Skovron ML, et al. HLA-B35 is associated with accelerated progression to AIDS. J Acquir Immune Defic Syndr 1992; 5:37-45.
9. Fiebig EW, Wright DJ, Rawal BD, et al. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS 2003; 17:1871-1879.
10. Rosenberg ES, Graham BS, Chan ES, et al. Safety and immunogenicity of therapeutic DNA vaccination in individuals treated with antiretroviral therapy during acute/early HIV-1 infection. PLoS ONE 2010; 5:e10555.
11. Davey RT, Jr., Bhat N, Yoder C, et al. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci U S A 1999; 96:15109-15114.
12. Li J. Analysis of analytic treatment interruption in past ACTG studies. Symposium II, Intensely monitored antiretroviral pause. Annual ACTG Network Meeting. 23-24 June 2014. Washington, DC, USA.
13. Rosenberg ES, Altfeld M, Poon SH, et al. Immune control of HIV-1 after early treatment of acute infection. Nature 2000; 407:523-526.
14. Ngo-Giang-Huong N, Deveau C, Da Silva I, et al. Proviral HIV-1 DNA in subjects followed since primary HIV-1 infection who suppress plasma viral load after one year of highly active antiretroviral therapy. AIDS 2001; 15:665-673.
15. Lodi S, Meyer L, Kelleher AD, et al. Immunovirologic control 24 months after interruption of antiretroviral therapy initiated close to HIV seroconversion. Arch Intern Med 2012; 172:1252-1255.
16. Williams JP, Hurst J, Stohr W, et al. HIV-1 DNA predicts disease progression and post-treatment virological control. eLIFE 2014; 3:e03821.
17. Ananworanich J, Schuetz A, Vandergeeten C, et al. Impact of multi-targeted antiretroviral treatment on gut T cell depletion and HIV reservoir seeding during acute HIV infection. PLoS ONE 2012; 7:e33948.
18. Scott-Algara D, Didier C, Arnold V, et al. Post-treatment controllers have particular NK cells with high anti-HIV capacity: VISCONTI study. Conference on Retroviruses and Opportunistic Infections. 23-26 February 2015, Seattle, WA, USA. Abstract 52.